SWOBY Valuation - Is Swedish Orphan Biovitrum AB (publ) Over or Undervalued?
Comprehensive analysis of Swedish Orphan Biovitrum AB (publ) valuation metrics including P/E, P/B, P/S, and EV/EBITDA ratios
Current Stock Price
$20.87
Market Cap
$15.10B
Valuation Date
Apr 21, 2026
Valuation Verdict
Potentially Overvalued
Based on valuation multiples, SWOBY appears expensive relative to fundamentals. 2 key metrics suggest premium pricing.
Key Valuation Metrics
These four fundamental valuation ratios help determine if SWOBY is trading at a fair price relative to its earnings, assets, revenue, and cash flow generation.
How to Interpret These Metrics
How SWOBY Compares to Peers
What This Means for Investors
Premium Valuation Alert
Swedish Orphan Biovitrum AB (publ) (SWOBY) is trading at premium valuation multiples, suggesting the market has high expectations for future growth. While this doesn't automatically mean the stock will decline, it does indicate limited margin of safety. Investors should carefully evaluate whether the company's growth prospects justify the current valuation or if they're paying too much for the stock.
Bullish Considerations
Bearish Considerations
- P/E ratio significantly above average
- High premium to book value
- Multiple metrics indicate overvaluation
Complete Your Analysis
Valuation is just one piece of the puzzle. Get the complete picture of SWOBY with our comprehensive analysis tools.
Full Stock Analysis
Complete financials, charts, and metrics
Should I Buy SWOBY?
AI-powered investment recommendation
Price Forecast
Future price targets and predictions
Analyst Ratings
Wall Street consensus and targets
Deep Valuation Analysis
DCF model and intrinsic value
Latest News
Breaking news and market sentiment
Frequently Asked Questions
What is SWOBY's P/E ratio and what does it mean?
SWOBY has a P/E (Price-to-Earnings) ratio of 260.88. This means investors are paying $260.88 for every $1 of annual earnings. A lower P/E generally suggests better value, but it's important to compare against industry peers and growth prospects. The market average P/E is typically 15-20x.
Is SWOBY stock overvalued or undervalued?
Based on our analysis of key valuation metrics (P/E, P/B, P/S, EV/EBITDA), SWOBY appears potentially overvalued. Based on valuation multiples, SWOBY appears expensive relative to fundamentals. 2 key metrics suggest premium pricing. However, valuation is just one factor to consider alongside growth prospects, competitive position, and market conditions.
What is a good P/E ratio for SWOBY?
There's no single "good" P/E ratio as it varies by industry and growth stage. For Swedish Orphan Biovitrum AB (publ), compare the current P/E of 260.88 against: (1) Industry peers, (2) Historical average P/E for SWOBY, (3) Expected earnings growth rate. High-growth companies often justify higher P/E ratios, while mature companies typically trade at lower multiples.
How do I use valuation ratios to make investment decisions?
Valuation ratios are screening tools, not buy/sell signals. Use them to: (1) Compare SWOBY against competitors, (2) Identify potential over/undervaluation, (3) Understand what you're paying for earnings, assets, or sales. Combine valuation analysis with fundamental research, growth prospects, and technical analysis for comprehensive decision-making.
What is EV/EBITDA and why does it matter?
EV/EBITDA (Enterprise Value to EBITDA) is 14.03 for SWOBY. This ratio is useful because it accounts for debt and excludes non-cash expenses, making it better for comparing companies with different capital structures. Lower EV/EBITDA generally indicates better value. It's particularly useful for comparing companies in capital-intensive industries.
Disclaimer: This valuation analysis is for informational and educational purposes only and should not be considered investment advice. Valuation metrics are just one factor in investment decisions. Always conduct comprehensive research and consult with a qualified financial advisor before making investment decisions. Past performance and current valuations do not guarantee future results.